Skip to main content

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Publication ,  Journal Article
Davies, MJ; Aroda, VR; Collins, BS; Gabbay, RA; Green, J; Maruthur, NM; Rosas, SE; Del Prato, S; Mathieu, C; Mingrone, G; Rossing, P; Buse, JB ...
Published in: Diabetes Care
November 1, 2022

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Diabetes Care

DOI

EISSN

1935-5548

Publication Date

November 1, 2022

Volume

45

Issue

11

Start / End Page

2753 / 2786

Location

United States

Related Subject Headings

  • United States
  • Hypoglycemic Agents
  • Hyperglycemia
  • Humans
  • Glucagon-Like Peptide-1 Receptor
  • Europe
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 2
  • Consensus
  • Adult
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., … Buse, J. B. (2022). Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 45(11), 2753–2786. https://doi.org/10.2337/dci22-0034
Davies, Melanie J., Vanita R. Aroda, Billy S. Collins, Robert A. Gabbay, Jennifer Green, Nisa M. Maruthur, Sylvia E. Rosas, et al. “Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetes Care 45, no. 11 (November 1, 2022): 2753–86. https://doi.org/10.2337/dci22-0034.
Davies, Melanie J., et al. “Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetes Care, vol. 45, no. 11, Nov. 2022, pp. 2753–86. Pubmed, doi:10.2337/dci22-0034.
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753–2786.

Published In

Diabetes Care

DOI

EISSN

1935-5548

Publication Date

November 1, 2022

Volume

45

Issue

11

Start / End Page

2753 / 2786

Location

United States

Related Subject Headings

  • United States
  • Hypoglycemic Agents
  • Hyperglycemia
  • Humans
  • Glucagon-Like Peptide-1 Receptor
  • Europe
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 2
  • Consensus
  • Adult